Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

Phase 4 Completed 30 enrolled National Heart Institute, Mexico National Council of Science and Technology, Mexico · collab Universidad Nacional Autonoma de Mexico · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The present study aims to investigate the effect of pioglitazone (30 mg/day) on endothelial function in premenopausal women with SLE (systemic lupus erythematosus). Patients with hypertension, endocrine, hepatic or renal diseases will not be included, or pregnant /breast feeding women. This is a randomized, double blind, placebo controlled study.

Timeline

Start: 2007-03
Primary completion: 2012-01
Completion: 2012-01

Publications

Juarez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, Caracas-Portilla NA, Posadas-Sanchez R, Cardoso-Saldana GC, Goycochea-Robles MV, Silveira LH, Lino-Perez L, Mas-Oliva J, Perez-Mendez O, Posadas-Romero C. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. Lupus. 2012 Jan;21(1):27-35. doi: 10.1177/0961203311422096. Epub 2011 Oct 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pioglitazone	Small molecule	30 mg	—

Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

Summary

Timeline

Publications

Drugs

Indications